Related Experiment Video
Updated: May 29, 2026
06:39
Bioluminescence Imaging of Heme Oxygenase-1 Upregulation in the Gua Sha Procedure
Published on: August 28, 2009
Effect of heme oxygenase-1 polymorphisms on lung function and gene expression.
Goh Tanaka1, Farzian Aminuddin, Loubna Akhabir
1UBC James Hogg Research Center, Providence Heart + Lung Institute, St, Paul's Hospital, Vancouver, B.C., Canada.
BMC Medical Genetics
|September 10, 2011
Summary
Genetic variations in the Heme oxygenase-1 (HMOX1) gene were not associated with lung function decline in smokers with Chronic Obstructive Pulmonary Disease (COPD). Promoter polymorphisms did not significantly affect HMOX1 gene regulation.
Area of Science:
- Genetics
- Pulmonology
- Molecular Biology
Background:
- Smoking-induced oxidative stress is implicated in Chronic Obstructive Pulmonary Disease (COPD) pathogenesis.
- Heme oxygenase-1 (HMOX1) is an antioxidant enzyme induced by oxidative stress, potentially protective in the lungs.
Purpose of the Study:
- To investigate the association between HMOX1 gene polymorphisms and lung function decline in COPD patients.
- To determine the functional effects of HMOX1 variants on gene expression.
Main Methods:
- Genotyped five single nucleotide polymorphisms (SNPs) in the HMOX1 gene in Caucasian smokers from the NHLBI Lung Health Study.
- Utilized reporter gene assays to assess the impact of promoter polymorphisms on HMOX1 gene expression.
- Investigated the effect of a specific SNP (rs2071749) on HMOX1 gene expression in alveolar macrophages.
Main Results:
- A nominal association between an intronic HMOX1 SNP (rs2071749) and lung function decline was observed but did not withstand multiple comparison correction.
- Reporter gene assays showed no significant effect of tested HMOX1 promoter polymorphisms on gene expression.
- No impact of rs2071749 on HMOX1 gene expression was detected in alveolar macrophages.
Conclusions:
- The studied HMOX1 single nucleotide polymorphisms (SNPs) were not significantly associated with lung function decline in COPD patients.
- No evidence was found that HMOX1 promoter polymorphisms influence the regulation of the HMOX1 gene.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...